Conclusions: Our research revealed that ECH has the capability to modulate ferroptosis via the Nrf2-HMOX1pathway, consequently mitigating the progression of MASLD. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatotic liver disease.